Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EUCR

Eucrates Biomedical Acquisition (EUCR) Stock Price, News & Analysis

Eucrates Biomedical Acquisition logo

About Eucrates Biomedical Acquisition Stock (NASDAQ:EUCR)

Key Stats

Today's Range
$10.02
$10.04
50-Day Range
$10.04
$10.25
52-Week Range
$9.87
$10.25
Volume
12,700 shs
Average Volume
2,287 shs
Market Capitalization
$42.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive EUCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eucrates Biomedical Acquisition and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EUCR Stock News Headlines

The End of Elon Musk…?
While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the verge of its biggest breakthrough yet — a revolutionary form of “Manifested AI” that Forbes has called a multi-trillion-dollar opportunity, potentially sparking a 25,000% growth market and setting up what he believes could be the greatest corporate comeback in history.tc pixel
8-K: Eucrates Biomedical Acquisition Corp.
See More Headlines

EUCR Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Eucrates Biomedical Acquisition investors own include Sprott Focus Trust (FUND), Meta Platforms (META), ETFMG Alternative Harvest ETF (MJX), New Zealand Energy (NZ), Strathcona Resources (SCR) and

Company Calendar

Today
10/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
Holding & other investment offices
Sub-Industry
N/A
Current Symbol
NASDAQ:EUCR
CIK
1822929
Web
N/A
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$2.42 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-62.82%
Return on Assets
2.95%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.03
Quick Ratio
2.03

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
$0.81 per share
Price / Cash Flow
12.36
Book Value
($1.25) per share
Price / Book
-8.03

Miscellaneous

Outstanding Shares
4,210,000
Free Float
3,386,000
Market Cap
$42.27 million
Optionable
Not Optionable
Beta
-0.07
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:EUCR) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners